

## SDIR-4 PROGRAMME

**4<sup>th</sup> Congress of the  
Serbian Association for Cancer Research (SDIR)  
with international participation**

**“Bringing science to oncology  
practice: Where is Serbia?”**

**Belgrade, 3-5 October 2019**



## Thursday, October 3<sup>rd</sup> 2019

- 13.30 – 16.00 **REGISTRATION**
- 14.00 – 15.00 Pre-meeting educational symposium  
***Applying translational cancer research in molecular diagnostics: Serbian experience 1***  
Chairs: Siniša Radulović, Zvonko Magić
- 14.00 – 14.20 Mirjana Branković-Magić. **Hereditary breast/ovarian cancer: challenges of next generation sequencing.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 14.20 – 14.40 Milena Čavić, Radmila Janković. **Pharmacogenetics in clinical practice: how far have we come?**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 14.40 – 15.00 Bojana Cikota-Aleksić. **Detection of minimal residual disease in leukemia and lymphoma: are we changing definition and concept?**  
*Military Medical Academy, Belgrade, Serbia*
- 15.00 – 15.45 **Welcome cocktail**
- 15.45 – 16.25 Pre-meeting educational symposium  
***Applying translational cancer research in molecular diagnostics: Serbian experience 2***
- 15.45 – 16.05 Snežana Šušnjar. **How to estimate the indications for administration of adjuvant chemotherapy in patients with luminal HER2 negative breast cancer? The role of uPA and PAI-1 biomarkers.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 16.05 – 16.25 Marija Đorđić Crnogorac. **uPA and PAI-1: prognostic factors for early breast cancer.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*

## Friday, October 4<sup>th</sup> 2019

- 08.00 **REGISTRATION**
- 08.30 – 09.00 **CONGRESS WELCOME**
- 09.00 – 10.30 ***Session: Targeted & Immunotherapy in cancer: Biomarker-based approaches***  
Chairs: Siniša Radulović, Radmila Janković
- 09.00 – 09.30 Davorin Radosavljević. **Focus on lung adenocarcinoma.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*

- 09.30 – 10.00 Lidija Kandolf-Sekulović. **Focus on melanoma.**  
*Military Medical Academy, Belgrade, Serbia*
- 10.00 – 10.30 Short talks
- 10.00 – 10.10 Tijana Martinov. **SOX2-targeted T cell immunotherapy in multiple myeloma.**  
*Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America*
- 10.10 – 10.20 Vesna Ćorić. **Disturbed redox balance contributes clear renal cell carcinoma development and progression.**  
*Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia*
- 10.20 – 10.30 Vera Jokić. **The predictive value of haematological parameters on the progression-free survival in advanced lung adenocarcinoma patients treated with tyrosine kinase inhibitors in Serbia.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 10.30 – 11.00 **Lecture sponsored by Labena**  
Uršula Prosenč Zmrzljak, Rok Košir, Zoran Krivokapić, Dragica Radojković, Aleksandra Nikolić. **Detection of somatic mutations with ddPCR from liquid biopsy of CRC patients.**
- 11.00 – 11.30 **Coffee break**
- 11.30 – 13.00 **Session: New technologies and approaches of molecular diagnostics in hereditary cancer**  
Chair: Mirjana Branković-Magić
- 11.30 – 12.00 Vita Šetrajčič Dragoš, Srđan Novaković. **The relevance of molecular diagnostic in hereditary cancer.**  
*Institute of Oncology, Ljubljana, Slovenia*
- 12.00 – 12.30 Ana Krivokuća. **The importance of panel testing in high grade serous ovarian cancer.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 12.30 – 13.00 Short talks
- 12.30 – 12.40 Iva Kirac. **Genetic counselling unit-model and experience of University Hospital for Tumours in Croatia.**  
*University Hospital for Tumours, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia*
- 12.40 – 12.50 Milica Mihajlović. **rs2910164 variant in *mir-146a* gene in high risk hereditary breast and ovarian cancer cases.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 12.50 – 13.00 Jovana Bročić. **CDK4 codon 24 mutation status in familial melanoma patients - single center study.**  
*Institute for Medical Research, Military Medical Academy, Belgrade, Serbia*

- 13.00 – 13.30 **Lecture sponsored by Roche**  
**Precision medicine in oncology. The importance of genomic profiling.**
- 13.30 – 14.30 **Lunch**
- 14.30 – 15.30 **Poster session and coffee break**  
15.30 – 16.15 **Plenary lecture (EACR Sponsored)**  
Arkaitz Carracedo. **Disentangling the molecular drivers of prostate cancer progression.**  
*Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain*
- 16.15 – 16.30 **Lecture sponsored by Superlab.**  
Vladan Kocić. **Analytical instruments in cancer research.**
- 16.30 – 18.15 **Session: Current challenges and future perspectives of radiotherapy**  
Chairs: Tatjana Stanojković, Marina Nikitović
- 16.30 – 16.45 Milena Krajnovic. **DNA methylation as a potential predictor of tumor response to radiotherapy.**  
*Vinca Institute of Nuclear Sciences, Belgrade, Serbia*
- 16.45 – 17.00 Emina Mališić. **The role of single nucleotide polymorphisms in outcome and toxicity of radiotherapy for prostate cancer.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 17.00 – 17.15 Barbara Jožef. **Comet assay as a tool for evaluation of DNA damage in cancer patient treated with radiotherapy.**  
*Institute for Chemistry, Technology and Metallurgy, University of Belgrade, Belgrade, Serbia*
- 17.15 – 17.30 Vesna Stanković, Marina Nikitović. **Late genitourinary toxicity after conventionally fractionated conformal radiotherapy for localized prostate cancer.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 17.30 – 17.45 Jelena Bokun, Marina Nikitović. **Pediatric radiotherapy at IORS.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 17.45 – 18.00 Tatjana Arsenijević, Marina Nikitović. **Micro RNA in lung cancer as potential biomarkers.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 18.00– 18.15 Discussion
- 20.30 **Welcome Dinner**

## Saturday, October 5<sup>th</sup> 2019

- 09.00 – 11.00 **Session: The role of oxidative stress in drug resistance**  
Chair: Milica Pešić
- 09.00 – 09.30 Joanna Kopecka. **Targeting mitochondria to overcome multidrug resistance in cancer.**  
*Turin School of Medicine, University of Turin, Turin, Italy*
- 09.30 – 10.00 Ana Čipak Gašparović. **Lipid peroxidation - double edge sword in fighting cancer (stem) cells.**  
*Institute Ruđer Bošković, Zagreb, Croatia*
- 10.00 – 10.30 Short talks
- 10.00 – 10.10 Marina Filimonova. **Prospects for the use of NOS inhibitors in radiation therapy.**  
*Tsyb Medical Radiological Research Center, National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, Obninsk, Russia*
- 10.10 – 10.20 Marina Stamenković. **Repurposing of pantoprazole as anticancer drug through induction of apoptosis, modulation of autophagy and enhancement of the effect of vincristine in cancer cells.**  
*Institute for Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia*
- 10.20 – 10.30 Tamara Babić. **SMAD4 transcript analysis in human permanent cell lines.**  
*Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia*
- 10.30 – 11.00 Discussion
- 11.00 – 11.30 **Coffee break**
- 11.30 – 13.30 **Session: Innovative tools for advancing cancer research**  
Chairs: Engin Ulukaya, Jelena Grahovac
- 11.30 – 12.00 Engin Ulukaya. **Spheres: simple and quite reliable models in basic cancer research.**  
*Istinye University, Istanbul, Turkey*
- 12.00 – 12.30 Tijana Stanković. **Glioblastoma behaviour in 3D biomimetic systems.**  
*Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia*
- 12.30 – 13.00 Short talks
- 12.30 – 12.40 Marija Nešović, Jelena Dinić. **c-Src inhibitors pyrozolo[3,4-d]pyrimidines, Si306 and pro-Si306, evade multidrug resistant phenotype and suppress invasion in glioblastoma.**  
*Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia*
- 12.40 – 12.50 Sercan Ergün. **Prognostic significance of miR-494 in renal cell carcinoma.**  
*Faculty of Medicine, Ordu University, Altınordu, Ordu, Turkey*

- 12.50 – 13.00 Marija Vidosavljević. **Nischarin expression in melanoma.**  
*Institute of Oncology and Radiology of Serbia, Belgrade, Serbia*
- 13.00 – 13.30 Discussion
- 13.30 – 14.30 **Lunch**
- 14.30 – 15.00 **Closing remarks and best poster award**